Complementary Assessment of Abdominopelvic Disorders with PET/CT and MRI

PET Clinics

Volumn 3, Issue 3, 2008, Pages 435-449

  Hustinx, Roland ^a   Torigian, Drew A ^b   Namur, Gauthier ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cervical cancer; Crohn's disease; Hepatic metastases; Pancreatic cancer; PET CT; PET MR imaging; Positron emission tomography; Rectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIAGNOSTIC ACCURACY; DIGESTIVE SYSTEM DISEASE; ENDOSCOPIC ECHOGRAPHY; HUMAN; HYSTERECTOMY; LIVER METASTASIS; LIVER SURGERY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CYST; PELVIS LYMPHADENECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; RECTUM CANCER; RECTUM SURGERY; REVIEW; SENSITIVITY AND SPECIFICITY; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 67249135790     PISSN: 15568598     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cpet.2009.02.002     Document Type: Review

References (89)

1. Kitajima K., Murakami K., Yamasaki E., et al. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Eur J Nucl Med Mol Imaging 35 8 (2008) 1439-1448
2. Schaefer N.G., Hany T.F., Taverna C., et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology 232 3 (2004) 823-829
3. Rodriguez-Vigil B., Gomez-Leon N., Pinilla I., et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med 47 10 (2006) 1643-1648
4. Strobel K., Heinrich S., Bhure U., et al. Contrast-enhanced 18F-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 49 9 (2008) 1408-1413
5. Pichler B.J., Wehrl H.F., and Judenhofer M.S. Latest advances in molecular imaging instrumentation. J Nucl Med 49 Suppl 2 (2008) 5S-23S
6. Kamangar F., Dores G.M., and Anderson W.F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24 14 (2006) 2137-2150
7. American Cancer Society. Cancer facts and figures 2008. Atlanta: American Cancer Society; 2008.
8. Benedet J.L., Bender H., Jones III H., et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet: The official organ of the International Federation of Gynaecology and Obstetrics 70 2 (2000) 209-262
9. Whitcomb B.P. Gynecologic malignancies. Surg Clin North Am 88 2 (2008) 301-317 vi
10. Petignat P., and Loubeyre P. Should we modify the current FIGO staging system for early-stage cervical cancer?. Expert Rev Anticancer Ther 8 7 (2008) 1015-1017
11. Lagasse L.D., Creasman W.T., Shingleton H.M., et al. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol 9 1 (1980) 90-98
12. Beiner M.E., and Covens A. Surgery insight: radical vaginal trachelectomy as a method of fertility preservation for cervical cancer. Nat Clin Pract Oncol 4 6 (2007) 353-361
13. Bipat S., Glas A.S., van der Velden J., et al. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. Gynecol oncol 91 1 (2003) 59-66
14. Hricak H., Gatsonis C., Coakley F.V., et al. Early invasive cervical cancer: CT and MR imaging in preoperative evaluation - ACRIN/GOG comparative study of diagnostic performance and interobserver variability. Radiology 245 2 (2007) 491-498
15. Magne N., Chargari C., Vicenzi L., et al. New trends in the evaluation and treatment of cervix cancer: the role of FDG-PET. Cancer Treat Rev 34 8 (2008) 671-681
16. Selman T.J., Mann C., Zamora J., et al. Diagnostic accuracy of tests for lymph node status in primary cervical cancer: a systematic review and meta-analysis. CMAJ 178 7 (2008) 855-862
17. Loft A., Berthelsen A.K., Roed H., et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: a prospective study. Gynecol Oncol 106 1 (2007) 29-34
18. Sironi S., Buda A., Picchio M., et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology 238 1 (2006) 272-279
19. Chou H.H., Chang T.C., Yen T.C., et al. Low value of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy. J Clin Oncol 24 1 (2006) 123-128
20. Park W., Park Y.J., Huh S.J., et al. The usefulness of MRI and PET imaging for the detection of parametrial involvement and lymph node metastasis in patients with cervical cancer. Jpn J Clin Oncol 35 5 (2005) 260-264
21. Choi H.J., Roh J.W., Seo S.S., et al. Comparison of the accuracy of magnetic resonance imaging and positron emission tomography/computed tomography in the presurgical detection of lymph node metastases in patients with uterine cervical carcinoma: a prospective study. Cancer 106 4 (2006) 914-922
22. Husain A., Akhurst T., Larson S., et al. A prospective study of the accuracy of 18Fluorodeoxyglucose positron emission tomography (18FDG PET) in identifying sites of metastasis prior to pelvic exenteration. Gynecol Oncol 106 1 (2007) 177-180
23. Yeh L.S., Hung Y.C., Shen Y.Y., et al. Detecting para-aortic lymph nodal metastasis by positron emission tomography of 18F-fluorodeoxyglucose in advanced cervical cancer with negative magnetic resonance imaging findings. Oncol Rep 9 6 (2002) 1289-1292
24. Yildirim Y., Sehirali S., Avci M.E., et al. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings. Gynecol Oncol 108 1 (2008) 154-159
25. Boughanim M., Leboulleux S., Rey A., et al. Histologic results of para-aortic lymphadenectomy in patients treated for stage IB2/II cervical cancer with negative [18F]fluorodeoxyglucose positron emission tomography scans in the para-aortic area. J Clin Oncol 26 15 (2008) 2558-2561
26. Chao A., Ho K.C., Wang C.C., et al. Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases. Gynecol Oncol 110 2 (2008) 172-178
27. Ma S.Y., See L.C., Lai C.H., et al. Delayed (18)F-FDG PET for detection of paraaortic lymph node metastases in cervical cancer patients. J Nucl Med 44 11 (2003) 1775-1783
28. Yen T.C., Ng K.K., Ma S.Y., et al. Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer. J Clin Oncol 21 19 (2003) 3651-3658
29. Narayan K., Fisher R.J., and Bernshaw D. Patterns of failure and prognostic factor analyses in locally advanced cervical cancer patients staged by magnetic resonance imaging and treated with curative intent. Int J Gynecol Cancer 18 3 (2008) 525-533
30. Hsu C.T., Cheng Y.S., and Su S.C. Prognosis of uterine cervical cancer with extensive lymph node metastases. Special emphasis on the value of pelvic lymphadenectomy in the surgical treatment of uterine cervical cancer. Am J Obstet Gynecol 114 7 (1972) 954-962
31. LaPolla J.P., Schlaerth J.B., Gaddis O., et al. The influence of surgical staging on the evaluation and treatment of patients with cervical carcinoma. Gynecol Oncol 24 2 (1986) 194-206
32. Grigsby P.W., Siegel B.A., and Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 19 17 (2001) 3745-3749
33. Miller T.R., Pinkus E., Dehdashti F., et al. Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer. J Nucl Med 44 2 (2003) 192-197
34. Unger J.B., Lilien D.L., Caldito G., et al. The prognostic value of pretreatment 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography scan in women with cervical cancer. Int J Gynecol Cancer 17 5 (2007) 1062-1067
35. Yen T.C., See L.C., Lai C.H., et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur J Nucl Med Mol Imaging 35 3 (2008) 493-501
36. Faria S.C., Tamm E.P., Loyer E.M., et al. Diagnosis and staging of pancreatic tumors. Semin Roentgenol 39 3 (2004) 397-411
37. Bipat S., Phoa S.S., van Delden O.M., et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 29 4 (2005) 438-445
38. Delbeke D., and Pinson C.W. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 11 1 (2004) 4-10
39. Zimny M., Bares R., Fass J., et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24 6 (1997) 678-682
40. Zimny M., Buell U., Diederichs C.G., et al. False-positive FDG PET in patients with pancreatic masses: an issue of proper patient selection?. Eur J Nucl Med 25 9 (1998) 1352
41. Shreve P.D. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease. Eur J Nucl Med 25 3 (1998) 259-264
42. Farma J.M., Santillan A.A., Melis M., et al. PET/CT fusion scan enhances CT staging in patients with pancreatic neoplasms. Ann Surg Oncol 15 9 (2008) 2465-2471
43. Heinrich S., Goerres G.W., Schafer M., et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 242 2 (2005) 235-243
44. Taylor M., Warnock G.L., Powell J., et al. Canadian Association of General Surgeons and American College of Surgeons evidence based reviews in surgery. 22. The use of PET/CT scanning on the management of resectable pancreatic cancer. Can J Surg 50 5 (2007) 400-402
45. Sahani D.V., Shah Z.K., Catalano O.A., et al. Radiology of pancreatic adenocarcinoma: current status of imaging. J Gastroenterol Hepatol 23 1 (2008) 23-33
46. Sakai Y., Tsuyuguchi T., Tsuchiya S., et al. Diagnostic value of MRCP and indications for ERCP. Hepatogastroenterology 54 80 (2007) 2212-2215
47. Katz D.S., Friedel D.M., Kho D., et al. Relative accuracy of CT and MRI for characterization of cystic pancreatic masses. AJR Am J Roentgenol 189 3 (2007) 657-661
48. Visser B.C., Yeh B.M., Qayyum A., et al. Characterization of cystic pancreatic masses: relative accuracy of CT and MRI. AJR Am J Roentgenol 189 3 (2007) 648-656
49. Balci N.C., and Semelka R.C. Radiologic features of cystic, endocrine and other pancreatic neoplasms. Eur J Radiol 38 2 (2001) 113-119
50. Sperti C., Pasquali C., Decet G., et al. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study. J Gastrointest Surg 9 1 (2005) 22-28 discussion 8-9
51. Sperti C., Bissoli S., Pasquali C., et al. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg 246 6 (2007) 932-937 discussion 7-9
52. Mansour J.C., Schwartz L., Pandit-Taskar N., et al. The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg 10 10 (2006) 1354-1360
53. Tann M., Sandrasegaran K., Jennings S.G., et al. Positron-emission tomography and computed tomography of cystic pancreatic masses. Clin Radiol 62 8 (2007) 745-751
54. Nagy V.M. Updating the management of rectal cancer. J Gastrointestin Liver Dis 17 1 (2008) 69-74
55. Bipat S., Glas A.S., Slors F.J., et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging-a meta-analysis. Radiol 232 3 (2004) 773-783
56. Nagtegaal I.D., and Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 26 2 (2008) 303-312
57. MERCURY study group. Extramural depth of tumor invasion at thin-section MR in patients with rectal cancer: results of the MERCURY study. Radiology 243 1 (2007) 132-139
58. Sauer R., Becker H., Hohenberger W., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351 17 (2004) 1731-1740
59. Lahaye M.J., Engelen S.M., Nelemans P.J., et al. Imaging for predicting the risk factors-the circumferential resection margin and nodal disease-of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR 26 4 (2005) 259-268
60. Abdel-Nabi H., Doerr R.J., Lamonica D.M., et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 206 3 (1998) 755-760
61. Kantorova I., Lipska L., Belohlavek O., et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 44 11 (2003) 1784-1788
62. Bassi M.C., Turri L., Sacchetti G., et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 70 5 (2008) 1423-1426
63. Davey K., Heriot A.G., Mackay J., et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum 51 7 (2008) 997-1003
64. Gearhart S.L., Frassica D., Rosen R., et al. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 13 3 (2006) 397-404
65. Park I.J., Kim H.C., Yu C.S., et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 32 9 (2006) 941-947
66. Capirci C., Rampin L., Erba P.A., et al. Sequential FDG-PET/CT reliably predicts response of locally advanced rectal cancer to neo-adjuvant chemo-radiation therapy. Eur J Nucl Med Mol Imaging 34 10 (2007) 1583-1593
67. Cascini G.L., Avallone A., Delrio P., et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. J Nucl Med 47 8 (2006) 1241-1248
68. Konski A., Li T., Sigurdson E., et al. Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys (2008) in press
69. Kalff V., Ware R., Heriot A., et al. Radiation changes do not interfere with postchemoradiation restaging of patients with rectal cancer by FDG PET/CT before curative surgical therapy. Int J Radiat Oncol Biol Phys (2008) in press
70. Pawlik T.M., Schulick R.D., and Choti M.A. Expanding criteria for resectability of colorectal liver metastases. Oncol 13 1 (2008) 51-64
71. Kinkel K., Lu Y., Both M., et al. Detection of hepatic metastases from cancers of the gastrointestinal tract by using noninvasive imaging methods (US, CT, MR imaging, PET): a meta-analysis. Radiology 224 3 (2002) 748-756
72. Schima W., Kulinna C., Langenberger H., et al. Liver metastases of colorectal cancer: US, CT or MR?. Cancer Imaging 5 Spec No A (2005) S149-S156
73. Selzner M., Hany T.F., Wildbrett P., et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?. Ann Surg 240 6 (2004) 1027-1034 discussion 35-6
74. Rappeport E.D., Loft A., Berthelsen A.K., et al. Contrast-enhanced FDG-PET/CT vs. SPIO-enhanced MRI vs. FDG-PET vs. CT in patients with liver metastases from colorectal cancer: a prospective study with intraoperative confirmation. Acta Radiol 48 4 (2007) 369-378
75. Kong G., Jackson C., Koh D.M., et al. The use of (18)F-FDG PET/CT in colorectal liver metastases-comparison with CT and liver MRI. Eur J Nucl Med Mol Imaging 35 7 (2008) 1323-1329
76. Soyka J.D., Veit-Haibach P., Strobel K., et al. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?. J Nucl Med 49 3 (2008) 354-361
77. Cantwell C.P., Setty B.N., Holalkere N., et al. Liver lesion detection and characterization in patients with colorectal cancer: a comparison of low radiation dose non-enhanced PET/CT, contrast-enhanced PET/CT, and liver MRI. J Comput Assist Tomogr 32 5 (2008) 738-744
78. Cellier C., Sahmoud T., Froguel E., et al. Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives. Gut 35 2 (1994) 231-235
79. Malago R., Manfredi R., Benini L., et al. Assessment of Crohn's disease activity in the small bowel with MR-enteroclysis: clinico-radiological correlations. Abdom Imaging 33 6 (2008) 669-675
80. Sinha R., Nwokolo C., and Murphy P.D. Magnetic resonance imaging in Crohn's disease. BMJ 336 7638 (2008) 273-276
81. Desmond A.N., O'Regan K., Curran C., et al. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut 57 11 (2008) 1524-1529
82. Peloquin J.M., Pardi D.S., Sandborn W.J., et al. Diagnostic ionizing radiation exposure in a population-based cohort of patients with inflammatory bowel disease. Am J Gastroenterol 103 8 (2008) 2015-2022
83. Kuehle C.A., Langhorst J., Ladd S.C., et al. Magnetic resonance colonography without bowel cleansing: a prospective cross sectional study in a screening population. Gut 56 8 (2007) 1079-1085
84. Florie J., Wasser M.N., Arts-Cieslik K., et al. Dynamic contrast-enhanced MRI of the bowel wall for assessment of disease activity in Crohn's disease. AJR Am J Roentgenol 186 5 (2006) 1384-1392
85. Negaard A., Paulsen V., Sandvik L., et al. A prospective randomized comparison between two MRI studies of the small bowel in Crohn's disease, the oral contrast method and MR enteroclysis. Eur Radiol 17 9 (2007) 2294-2301
86. Loffler M., Weckesser M., Franzius C., et al. High diagnostic value of 18F-FDG-PET in pediatric patients with chronic inflammatory bowel disease. Ann N Y Acad Sci 1072 (2006) 379-385
87. Skehan S.J., Issenman R., Mernagh J., et al. 18F-fluorodeoxyglucose positron tomography in diagnosis of paediatric inflammatory bowel disease. Lancet 354 9181 (1999) 836-837
88. Meisner R.S., Spier B.J., Einarsson S., et al. Pilot study using PET/CT as a novel, noninvasive assessment of disease activity in inflammatory bowel disease. Inflamm Bowel Dis 13 8 (2007) 993-1000
89. Louis E., Ancion G., Colard A., et al. Noninvasive assessment of Crohn's disease intestinal lesions with (18)F-FDG PET/CT. J Nucl Med 48 7 (2007) 1053-1059